Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reza Nabizadeh

Neurology Charlotte, NC Medical Doctor

NPI 1356507644 CMS profile 198022

2608 E 7Th St, Charlotte, NC 28204

Open in the dashboard

General payments

$6,935

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Reza Nabizadeh of Charlotte, NC is reported in the CMS Open Payments database as having received $6,935 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,331 55
2024 General $936 43
2023 General $990 46
2022 General $1,149 63
2021 General $768 53
2020 General $641 36
2019 General $1,119 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reza Nabizadeh
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Reza Nabizadeh were reported at $1,331. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Reza Nabizadeh Neurology median Middle half National median
2019 $1,119 $474 $118–$2,177 $163
2020 $641 $367 $82–$2,309 $114
2021 $768 $438 $104–$2,547 $132
2022 $1,149 $442 $103–$2,388 $149
2023 $990 $464 $119–$2,312 $160
2024 $936 $468 $119–$2,323 $164
2025 $1,331 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $2,609 125 payments
  2. Neurelis, Inc. $826 39 payments
  3. Jazz Pharmaceuticals Inc. $619 24 payments
  4. Supernus Pharmaceuticals, Inc. $559 47 payments
  5. Greenwich Biosciences, Inc. $377 16 payments
  6. Aquestive Therapeutics, Inc. $253 14 payments
  7. Aucta Pharmaceuticals, Inc. $247 14 payments
  8. Eisai Inc. $179 8 payments
  9. Sunovion Pharmaceuticals Inc. $144 9 payments
  10. Mallinckrodt Enterprises LLC $127 5 payments
  11. Other $995 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,935 350 payments
Products named General payments · program years 2019–2025
  1. Briviact $1,405 72 payments
  2. Epidiolex $996 40 payments
  3. VALTOCO $826 39 payments
  4. Fintepla $708 31 payments
  5. Nayzilam $364 16 payments
  6. OXTELLAR XR $330 24 payments
  7. Motpoly XR $247 14 payments
  8. SYMPAZAN $212 12 payments
  9. Fycompa $166 7 payments
  10. TROKENDI XR $163 18 payments
  11. Other $1,378 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record